Maximilian Jara1, Tomasz Dziodzio2, Maciej Malinowski2,3, Katja Lüttgert2, Radoslav Nikolov2, Paul Viktor Ritschl2,4, Robert Öllinger2, Johann Pratschke2, Martin Stockmann2,5. 1. Department of Surgery, Campus Charité Mitte - Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany. maximilian.jara@charite.de. 2. Department of Surgery, Campus Charité Mitte - Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany. 3. Department of General, Visceral, Vascular and Pediatric Surgery, University of The Saarland, Homburg, Saar, Germany. 4. BIH Charité Clinician Scientist Program, Berlin Institute of Health (BIH), Berlin, DE, Germany. 5. Department of General, Visceral and Vascular Surgery, Evangelisches Krankenhaus Paul Gerhardt Stift, Lutherstadt Wittenberg, Germany.
Abstract
BACKGROUND: MELD attempts to objectively predict the risk of mortality of patients with liver cirrhosis and is commonly used to prioritize organ allocation. Despite the usefulness of the MELD, updated metrics could further improve the accuracy of estimates of survival. AIMS: To assess and compare the prognostic ability of an enzymatic 13C-based liver function test (LiMAx) and distinct markers of liver function to predict 3-month mortality of patients with chronic liver failure. METHODS: We prospectively investigated liver function of 268 chronic liver failure patients without hepatocellular carcinoma. Primary study endpoint was liver-related death within 3 months of follow-up. Prognostic values were calculated using Cox proportional hazards and logistic regression analysis. RESULTS: The Cox proportional hazard model indicated that LiMAx (p < 0.001) and serum creatinine values (p < 0.001) were the significant parameters independently associated with the risk of liver failure-related death. Logistic regression analysis revealed LiMAx and serum creatinine to be independent predictors of mortality. Areas under the receiver-operating characteristic curves for MELD (0.86 [0.80-0.92]) and for a combined score of LiMAx and serum creatinine (0.83 [0.76-0.90]) were comparable. CONCLUSIONS: Apart from serum creatinine levels, enzymatic liver function measured by LiMAx was found to be an independent predictor of short-term mortality risk in patients with liver cirrhosis. A risk score combining both determinants allows reliable prediction of short-term prognosis considering actual organ function. Trial Registration Number (German Clinical Trials Register) # DRKS00000614.
BACKGROUND: MELD attempts to objectively predict the risk of mortality of patients with liver cirrhosis and is commonly used to prioritize organ allocation. Despite the usefulness of the MELD, updated metrics could further improve the accuracy of estimates of survival. AIMS: To assess and compare the prognostic ability of an enzymatic 13C-based liver function test (LiMAx) and distinct markers of liver function to predict 3-month mortality of patients with chronic liver failure. METHODS: We prospectively investigated liver function of 268 chronic liver failurepatients without hepatocellular carcinoma. Primary study endpoint was liver-related death within 3 months of follow-up. Prognostic values were calculated using Cox proportional hazards and logistic regression analysis. RESULTS: The Cox proportional hazard model indicated that LiMAx (p < 0.001) and serum creatinine values (p < 0.001) were the significant parameters independently associated with the risk of liver failure-related death. Logistic regression analysis revealed LiMAx and serum creatinine to be independent predictors of mortality. Areas under the receiver-operating characteristic curves for MELD (0.86 [0.80-0.92]) and for a combined score of LiMAx and serum creatinine (0.83 [0.76-0.90]) were comparable. CONCLUSIONS: Apart from serum creatinine levels, enzymatic liver function measured by LiMAx was found to be an independent predictor of short-term mortality risk in patients with liver cirrhosis. A risk score combining both determinants allows reliable prediction of short-term prognosis considering actual organ function. Trial Registration Number (German Clinical Trials Register) # DRKS00000614.
Authors: Robert A Fisher; Douglas M Heuman; Ann M Harper; Martha K Behnke; Alastair D Smith; Mark W Russo; Steven Zacks; John W McGillicuddy; James Eason; Michael K Porayko; Patrick Northup; Michael R Marvin; Johnathan Hundley; Satheesh Nair Journal: Ann Hepatol Date: 2012 Jan-Feb Impact factor: 2.400
Authors: Scott W Biggins; Harry J Rodriguez; Peter Bacchetti; Nathan M Bass; John P Roberts; Norah A Terrault Journal: Hepatology Date: 2005-01 Impact factor: 17.425
Authors: P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: K T Werner; Shawna Sando; Elizabeth J Carey; Hugo E Vargas; Thomas J Byrne; David D Douglas; M E Harrison; Jorge Rakela; Bashar A Aqel Journal: Dig Dis Sci Date: 2013-01-12 Impact factor: 3.199
Authors: Pratima Sharma; Douglas E Schaubel; Camelia S Sima; Robert M Merion; Anna S F Lok Journal: Gastroenterology Date: 2008-08-15 Impact factor: 22.682
Authors: Magnus F Kaffarnik; Johan F Lock; Hannah Vetter; Navid Ahmadi; Christian Lojewski; Maciej Malinowski; Peter Neuhaus; Martin Stockmann Journal: Crit Care Date: 2013-10-31 Impact factor: 9.097
Authors: Tomasz Dziodzio; Robert Öllinger; Wenzel Schöning; Antonia Rothkäppel; Radoslav Nikolov; Andrzej Juraszek; Paul V Ritschl; Martin Stockmann; Johann Pratschke; Maximilian Jara Journal: BMC Gastroenterol Date: 2020-08-12 Impact factor: 3.067